Argos Therapeutics, Inc. Study Confirms Optimal Quality Control Methods for Production of Its RNA-Based Immunotherapies

Published: Nov 16, 2012

DURHAM, N.C., Nov. 15, 2012 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced the publication of key findings that confirms the Company's current methods of analyzing RNA are robust and optimal for the assessment of RNA quality needed to develop the Company's novel immunotherapies. The study, which was published in the November issue of the Journal of Pharmaceutical and Biomedical Analysis, the journal of the American Association of Pharmaceutical Scientists, compared traditional slab electrophoresis currently in use at Argos to a newer microfluidics-based platform1 for performing various RNA analyses.

Back to news